Education
About Us
Working with TipRanks
Follow Us
PSCH - ETF AI Analysis
Top Page
Invesco S&P SmallCap Health Care ETF (PSCH)
Rating:66Neutral
Price Target:―
Positive Factors
Focused Health Care Exposure
The ETF is heavily invested in the health care sector, giving investors targeted access to small-cap health care companies.
Several Strong Top Holdings
Some of the largest positions, such as Krystal Biotech, Glaukos, Alkermes, and TransMedics Group, have shown strong year-to-date performance, helping support the fund’s returns.
Moderate Expense Ratio
The fund’s expense ratio is reasonable for a specialized small-cap sector ETF, helping keep ongoing costs from becoming too burdensome.
Negative Factors
Sector Concentration Risk
With the vast majority of assets in health care, the ETF is highly sensitive to downturns or regulatory changes affecting that single sector.
Mixed Performance Among Top Holdings
Several key holdings, including Arrowhead Pharmaceuticals, PTC Therapeutics, Radnet, Merit Medical Systems, Protagonist Therapeutics, and Teleflex, have shown weak year-to-date performance, which can drag on overall results.
Limited Geographic Diversification
The portfolio is almost entirely invested in U.S. companies, offering little diversification across different countries or regions.
PSCH vs. SPDR S&P 500 ETF (SPY)
AUM143.37M
RegionNorth America
Expense Ratio0.29%
Beta0.79
IssuerInvesco
Inception DateApr 07, 2010
Dividend Yield0.09%
Asset ClassEquity
Index TrackedS&P SmallCap 600 Capped Health Care Index - Benchmark TR Gross
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume18,088
30 Day Avg. Volume13,298
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
57.32Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering76
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PSCH Summary
The Invesco S&P SmallCap Health Care ETF (PSCH) invests in smaller U.S. health care companies by tracking the S&P SmallCap 600 Capped Health Care Index. It holds a mix of businesses in areas like drugs, biotech, medical devices, and health care services. Examples include Arrowhead Pharmaceuticals and Teleflex. Someone might consider this ETF if they want growth potential from innovative, younger health care companies and diversification across many small firms instead of picking single stocks. A key risk is that small health care stocks can be very volatile, so the ETF’s price can rise and fall sharply with the market and sector news.
How much will it cost me?The Invesco S&P SmallCap Health Care ETF (PSCH) has an expense ratio of 0.29%, meaning you’ll pay $2.90 per year for every $1,000 invested. This cost is slightly higher than average because the ETF focuses on a niche sector and tracks small-cap health care companies, which require more active management compared to broad-market passive ETFs.
What would affect this ETF?The Invesco S&P SmallCap Health Care ETF (PSCH) could benefit from advancements in biotechnology, pharmaceuticals, and medical devices, as small-cap companies often drive innovation in the health care sector. However, it may face challenges from rising interest rates, which can increase borrowing costs for smaller companies, and regulatory changes in the U.S. health care industry that could impact profitability. The ETF’s focus on U.S. small-cap health care stocks makes it sensitive to domestic economic conditions and sector-specific trends.
PSCH Top 10 Holdings
PSCH is a pure U.S. small-cap health care play, and its story is being written mostly by a handful of biotech and medical device names. Krystal Biotech, Alkermes, and TransMedics are the fund’s current engines, with rising share prices and upbeat growth narratives helping to pull the ETF higher. Glaukos has also been a steady contributor with solid momentum. On the flip side, Arrowhead Pharmaceuticals, PTC Therapeutics, and especially Teleflex have been lagging, acting like a headwind that partially offsets the strength from the fund’s faster-moving winners.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Krystal Biotech | 4.12% | $5.88M | $7.91B | 75.06% | 80 Outperform | |
| Glaukos | 3.66% | $5.23M | $6.26B | -25.52% | 61 Neutral | |
| Alkermes | 3.37% | $4.81M | $5.76B | -3.03% | 80 Outperform | |
| PTC Therapeutics | 3.33% | $4.75M | $5.69B | 42.78% | 72 Outperform | |
| Protagonist Therapeutics | 2.87% | $4.10M | $5.22B | 115.85% | 68 Neutral | |
| Radnet | 2.82% | $4.03M | $5.38B | 11.12% | 63 Neutral | |
| Merit Medical Systems | 2.82% | $4.02M | $4.82B | -24.98% | 68 Neutral | |
| Teleflex | 2.77% | $3.95M | $4.73B | -36.19% | 68 Neutral | |
| TransMedics Group | 2.67% | $3.80M | $4.56B | 87.17% | 77 Outperform | |
| BrightSpring Health Services, Inc. | 2.66% | $3.80M | $7.22B | 81.43% | 67 Neutral |
PSCH Technical Analysis
Negative
―
Price Trends
45.00
Negative
43.70
Negative
41.96
Positive
Market Momentum
-0.47
Positive
40.02
Neutral
30.54
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For PSCH, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 44.39, equal to the 50-day MA of 45.00, and equal to the 200-day MA of 41.96, indicating a neutral trend. The MACD of -0.47 indicates Positive momentum. The RSI at 40.02 is Neutral, neither overbought nor oversold. The STOCH value of 30.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PSCH.
PSCH Peer Comparison
Comparison Results
Performance Comparison
PSCH
Invesco S&P SmallCap Health Care ETF
43.19
-4.73
-9.87%
FXH
First Trust Health Care AlphaDEX Fund
―
―
―
RSPH
Invesco S&P 500 Equal Weight Health Care ETF
―
―
―
IHF
iShares U.S. Healthcare Providers ETF
―
―
―
PINK
Simplify Health Care ETF
―
―
―
PTH
Invesco DWA Healthcare Momentum ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents